Product lifecycle management
Product brand management
Market access / pricing / payment strategy (including commercial insurance)
Digital channel strategy
Real world researches
Clinical Development Regulatory Service
Clinical Operation Service
Data Management & Statistical Analysis
AI has an important impact on the clinical research process, alleviating various obstacles in data collection, tracing, monitoring, and imaging data evaluation, as well as improving quality and efficiency. Especially in the field of clinical trials, with the help of HLT's big data and artificial intelligence, clinical trials are managed with greater efficiency and precision.
Can Chen, Head of Digital Innovation at Happy Life Technology (HLT), and Yuzhu Ding, Data and Digital Manager in Novartis, presented at this year’s Sino-American Pharmaceutical Professionals Association (SAPA) Scientific Symposium held on May 22, 2021.
Multiple myeloma (MM) represents a big challenge for health care providers. Treating MM is complex and often involves several medications including immunotherapies, chemotherapy agents, and proteasome inhibitors. MM patients usually switch therapies when the disease progresses or shows drug resistance. However, physicians also switch medications for patients whose disease has not progressed. In fact, up to 50% of the MM patients in real-world settings experience a regimen switch without a relapse in China. Change of therapy adds to the complexity of treating MM and makes it challenge for physicians to choose the right therapies at the right time for the right patients. Real-world data helps HCPs and researchers estimate the true impact of each treatment options. HLT analyzes real-world treatment patterns and patient outcomes to provide valuable information about a product’s market impact.